Medical Marijuana: Sativex Wins FDA Approval for Trials in US 1/6/06

Drug War Chronicle, recent top items

more...

recent blog posts "In the Trenches" activist feed

SUBSCRIBE TODAY!!!


http://stopthedrugwar.org/chronicle/417/sativex.shtml

GW Pharmaceuticals, the maker of the sublingual, cannabis-based spray medication Sativex, announced Wednesday that it won US Food and Drug Administration (FDA) approval to proceed with Phase III clinical trials of the drug's efficacy in patients suffering from pain from advanced cancers. The FDA has accepted GW's bid to study the drug under its Investigational New Drug (IND) program.

Sativex is already on the market in Canada and has been approved for use in Spain, but its bid to win acceptance in Britain stumbled recently when an elderly women participating in Sativex trials died. The FDA based its approval in part on data generated by GW on Sativex in Europe.

The planned 250-patient study will evaluate the effects of Sativex in relieving average daily, reducing the use of opioid pain medications, and improving the quality of sleep and other quality of life indicators among patients.

"A previous Phase III clinical study showed that Sativex achieved a statistically significant improvement in pain relief in terminally ill cancer patients," said researcher, Dr. Russell K. Portenoy, Chairman of the Department of Pain Medicine and Palliative \Care at Beth Israel Medical Center in New York City. "Although opioids are highly effective analgesics, studies suggest that as many as one-third of patients with pain due to advanced cancer do not obtain adequate relief and new treatments are needed. Cannabinoid formulations may represent an important option in the future and the information obtained from clinical trials of Sativex will be critical in defining their role."

"Sativex seems to be a very promising treatment option for patients whose pain does not respond to current analgesics," said Dr. Nathaniel Katz, Assistant Professor of Anesthesia, Tufts University School of Medicine. "The clinical data thus far suggest that many patients who have been suffering with intractable pain may gain significant benefit from the use of Sativex. I welcome GW expanding its research program into the US."

GW stockholders and chronic pain patients may indeed welcome the FDA's approval of Sativex trials as one more step in bringing the drug to market in the US. But advocates of raw, smoked medical marijuana also worry whether approval of a cannabis-based medicine could cut the legs out from under the medical marijuana movement.

-- END --
Link to Drug War Facts
Please make a generous donation to support Drug War Chronicle in 2007!          

PERMISSION to reprint or redistribute any or all of the contents of Drug War Chronicle (formerly The Week Online with DRCNet is hereby granted. We ask that any use of these materials include proper credit and, where appropriate, a link to one or more of our web sites. If your publication customarily pays for publication, DRCNet requests checks payable to the organization. If your publication does not pay for materials, you are free to use the materials gratis. In all cases, we request notification for our records, including physical copies where material has appeared in print. Contact: StoptheDrugWar.org: the Drug Reform Coordination Network, P.O. Box 18402, Washington, DC 20036, (202) 293-8340 (voice), (202) 293-8344 (fax), e-mail drcnet@drcnet.org. Thank you.

Articles of a purely educational nature in Drug War Chronicle appear courtesy of the DRCNet Foundation, unless otherwise noted.

Issue #417 -- 1/6/06

Drug War Chronicle, recent top items

more...

recent blog posts "In the Trenches" activist feed

SUBSCRIBE TODAY!!!

Editorial: Arguments Best Set to Rest | Feature: Rhode Island Overrides Governor's Veto to Become 11th State Okaying Medical Marijuana | Feature: Medical Marijuana Refugee Running Out of Time, Options | Feature: Congressional Budget-Cutting Extends Even to Drug War Sacred Cows | Feature: Reformers Focus on Colorado, Nevada to Free the Weed in 2006 | Law Enforcement: This Week's Corrupt Cops Stories | Methamphetamine: Tennessee Creates Meth Offender Registry | Medical Marijuana: Sativex Wins FDA Approval for Trials in US | Europe: Ketamine Now Illegal in England | Latin America: DEA to Expand into Guyana | World-Wide: This Year's Global Marijuana March is Coming to a City Near You May 6 | New DRCNet Book Offer: "Tulia: Race, Cocaine, and Corruption in a Small Texas Town" | Web Scan: New England Journal of Medicine on the DEA vs. Oregon's Right to Die Law | Weekly: This Week in History | Weekly: The Reformer's Calendar |

Mail this article to a friend
Send us feedback on this article
This issue -- main page
This issue -- single-file printer version
Drug War Chronicle -- main page
Chronicle archives
Subscribe now!
Out from the Shadows HEA Drug Provision Drug War Chronicle Perry Fund DRCNet en EspaŮol Speakeasy Blogs About Us Home
Why Legalization? NJ Racial Profiling Archive Subscribe Donate DRCNet em PortuguÍs Latest News Drug Library Search
special friends links: SSDP - Flex Your Rights - IAL - Drug War Facts

StoptheDrugWar.org: the Drug Reform Coordination Network (DRCNet)
1623 Connecticut Ave., NW, 3rd Floor, Washington DC 20009 Phone (202) 293-8340 Fax (202) 293-8344 drcnet@drcnet.org